Schonfeld Strategic Advisors LLC Grows Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Schonfeld Strategic Advisors LLC raised its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 129.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 849,081 shares of the biotechnology company's stock after purchasing an additional 479,482 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 3.13% of Arcturus Therapeutics worth $14,409,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ARCT. Vanguard Group Inc. lifted its stake in Arcturus Therapeutics by 6.8% in the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock valued at $28,587,000 after buying an additional 107,635 shares during the period. Geode Capital Management LLC increased its stake in Arcturus Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock worth $9,421,000 after acquiring an additional 3,186 shares during the period. Empire Life Investments Inc. increased its stake in shares of Arcturus Therapeutics by 85.5% in the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after buying an additional 128,771 shares during the period. Northern Trust Corp lifted its stake in shares of Arcturus Therapeutics by 5.6% in the fourth quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company's stock worth $4,350,000 after acquiring an additional 13,582 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Arcturus Therapeutics by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock worth $3,526,000 after purchasing an additional 10,180 shares during the period. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Trading Down 6.4 %

ARCT traded down $0.83 during trading hours on Monday, hitting $12.01. The company's stock had a trading volume of 105,724 shares, compared to its average volume of 417,246. The stock has a market cap of $325.59 million, a price-to-earnings ratio of -5.41 and a beta of 3.41. The business's 50-day moving average price is $12.35 and its 200-day moving average price is $15.74. Arcturus Therapeutics Holdings Inc. has a 12 month low of $8.04 and a 12 month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

ARCT has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Wells Fargo & Company decreased their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. HC Wainwright reiterated a "buy" rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group lowered their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $59.20.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.